Study of Rapastinel as Monotherapy in Patients With MDD

Allergan

Status and phase: Terminated; Phase 3

Conditions: Depressive Disorder, Major

Treatments: Drug: Rapastinel; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT03560518

RAP-MD-32

Details and patient eligibility

About

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).

Enrollment: 439 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for MDD
• Current major depressive episode of at least 8 weeks and not exceeding 18 months in duration at Visit 1
• Treatment naive in the current episode or have inadequate response to 1-3 antidepressant therapies given at adequate dose and duration in the current episode
• If female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test

Exclusion criteria

• DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1
• Lifetime history of meeting DSM-5 criteria for:
• Schizophrenia spectrum or other psychotic disorder
• Bipolar or related disorder
• Major neurocognitive disorder
• Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study
• Dissociative disorder
• Posttraumatic stress disorder
• MDD with psychotic features
• Significant suicide risk, as judged by the Investigator

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

439 participants in 3 patient groups, including a placebo group

Rapastinel 450mg

Experimental group

Description:

Rapastinel 450 mg (prefilled syringe, weekly intravenous IV administration)

Treatment:

Drug: Rapastinel

Rapastinel 900mg

Experimental group

Description:

Rapastinel 900 mg (prefilled syringe, weekly intravenous IV administration)

Treatment:

Drug: Rapastinel

Placebo

Placebo Comparator group

Description:

Placebo (prefilled syringe, weekly IV administration)

Treatment:

Drug: Placebo